沃格光电(603773.SH)：航天CPI产品尚未实现量产 微流控生物芯片不涉及芯片设计和制造

Core Viewpoint - The company has not yet achieved mass production of its aerospace CPI products, and current applications involve only a single satellite's flexible solar wing with a small order value [1] Group 1: Product Development and Revenue Impact - The orders signed with relevant customers are in the product testing and validation phase, accounting for less than 0.1% of the company's projected revenue for 2025, indicating no significant impact on operational performance [1] - The company's microfluidic biochip business primarily utilizes glass-based TGV technology to provide necessary glass substrates or structural components for downstream clients, without involvement in chip design or manufacturing [1] Group 2: Financial Performance in Bio-Medical Sector - For the fiscal year 2025, the cumulative sales revenue from microfluidic-related products in the biomedical field is projected to be $10.79 million, representing a very small proportion of the company's overall revenue [1]